Standard BioTools Inc. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised

Standard BioTools Inc. (LAB) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised of $827.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions · last filed 2024-03-01

Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2023 was $827.00K, a 9.81% decline from fiscal 2022.
Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2022 was $917.00K, a 38.62% decline from fiscal 2021.
Standard BioTools Inc. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2021 was $1.49M.

Period end	Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 12 month
2023-12-31	$827.00K 10-K · filed 2024-03-01
2022-12-31	$917.00K 10-K · filed 2024-03-01
2021-12-31	$1.49M 10-K · filed 2023-03-14

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)	United States	$0.296B	-21.78
Vanda Pharmaceuticals Inc. (VNDA)	United States	$0.302B	-1.35
Fulcrum Therapeutics, Inc. (FULC)	United States	$0.289B	-3.28
Contineum Therapeutics, Inc. (CTNM)	United States	$0.289B	-4.40
GT Biopharma, Inc. (GTBP)	United States	$0.309B	-4.58
Perspective Therapeutics, Inc. (CATX)	United States	$0.284B	-3.34
Upstream Bio, Inc. (UPB)	United States	$0.284B	-2.42
ABEONA THERAPEUTICS INC. (ABEO)	United States	$0.312B	-5.63
Sagimet Biosciences Inc. (SGMT)	United States	$0.279B
Prelude Therapeutics Inc (PRLD)	United States	$0.318B	-7.01